Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Progress has been made in identifying and treating the disease, but the impact of federal cuts is yet to be borne out.

The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...

Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk smoldering multiple myeloma (SMM). The approval makes DARA SC, a subcutaneous ...